Related Experiment Video
Updated: Dec 16, 2025

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells
Published on: April 25, 2018
Long non‑coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR‑675
Yongzi Xu1, Yanhui Liu2, Zhenrong Li3
1Department of General Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China.
Abstract:
Sorafenib is the first‑line treatment for advanced hepatocellular carcinoma (HCC). Since many HCC patients experience drug resistance, there is an urgent need to discover more effective therapeutic strategies to overcome drug resistance. Long non‑coding RNAs (lncRNAs) play an important role in tumor drug resistance. However, research on the role of lncRNA H19 in sorafenib resistance in HCC is quite limited. In the present study, CCK‑8 assay, RT‑qPCR, EdU staining, immunofluorescence staining, and western blot analysis were used to detect the effect of lncRNA H19 on sorafenib resistance of HCC cells. H19 expression was found to be negatively related to sorafenib sensitivity in HCC cells. Knockdown of lncRNA H19 elevated sorafenib sensitivity by suppressing epithelial‑mesenchymal transition (EMT) in HCC cells. H19 upregulated miR‑675 expression. miR‑675 inhibitor decreased the cell viability in sorafenib‑treated HCC cells, while miR‑675 overexpression had the opposite effect on the treated cells. When the cells were pretreated with miR‑675 mimic, H19 siRNA did not alter the effect of miR‑675 on sorafenib sensitivity. In conclusion, our study provides new clues for further clinical treatment of sorafenib‑resistant liver cancer patients.
Insights
Long non-coding RNA H19 promotes sorafenib resistance in hepatocellular carcinoma (HCC) by upregulating miR-675 and enhancing epithelial-mesenchymal transition (EMT). Targeting H19 may offer new therapeutic strategies for drug-resistant liver cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Sorafenib is a first-line treatment for advanced hepatocellular carcinoma (HCC).
- Drug resistance in HCC limits treatment efficacy, necessitating novel therapeutic strategies.
- Long non-coding RNAs (lncRNAs) are implicated in tumor drug resistance, but the role of lncRNA H19 in HCC sorafenib resistance is underexplored.
Purpose of the Study:
- To investigate the role of lncRNA H19 in sorafenib resistance in HCC.
- To elucidate the underlying molecular mechanisms involving H19, miR-675, and epithelial-mesenchymal transition (EMT).
Main Methods:
- Cell Counting Kit-8 (CCK-8) assay for cell viability.
- Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for gene expression analysis.
- EdU staining, immunofluorescence staining, and western blot analysis to assess cellular proliferation, EMT markers, and protein expression.
Main Results:
- H19 expression was negatively correlated with sorafenib sensitivity in HCC cells.
- Knockdown of H19 increased sorafenib sensitivity by suppressing EMT.
- H19 upregulated miR-675; miR-675 inhibition decreased cell viability, while overexpression increased it in sorafenib-treated HCC cells.
- H19's effect on sorafenib sensitivity was dependent on miR-675 levels.
Conclusions:
- lncRNA H19 promotes sorafenib resistance in HCC.
- The H19/miR-675 axis plays a crucial role in regulating sorafenib sensitivity and EMT in HCC.
- Targeting H19 presents a potential therapeutic avenue for overcoming sorafenib resistance in liver cancer patients.
More Related Videos
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Types of RNA
RNA Performs Diverse...
Abnormal Proliferation

